Safety and Efficacy of TAF to Prevent MTCT of HBV in Middle/Late Pregnancies With High HBV DNA Load

Exclusion Criteria

• •Patients with antibodies against HIV, HCV, HDV, or other forms of chronic liver disease.
• •Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity.
• •Concurrent treatment with nephrotoxic drugs, glucocorticoids, cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators.
• •Ultra-sonographic evidence of fetal deformity, abnormal fetal development or placental abnormality.
• •Clinical signs of threatened miscarriage.
• •History of complication of pregnancy.
• •History of nucleoside analogues (NA) treatment.